GeoMap Focuses On China And South Korea COVID-19 Patient Recruitment
The award-winning global leader in digital patient recruitment GeoMap Clinical said it was seeing more demand for clinical trial patient recruitment in China and South Korea as the two regions reported a drop in COVID-19 infections.
The GeoMap Clinical Platform is the world’s most advanced geo-location/targeting and AI platform powered by specialist algorithms that find and screen the right people living or working near sites.
GeoMap is working closely with biotechs and CROs around the world to keep screening patients and connecting them with study coordinators online to support important ongoing clinical research amid the COVID-19 crisis.
The GeoMap Platform recruits for clinical trials in North America, Latin America, Australia, New Zealand, China, South Korea, Singapore, Thailand, and the EU.
“For all studies now it is important for patients to be screened online and then get to talk to a study coordinator about next steps because there are many alternatives to clinic visits that are now being offered.”
“Home visits, telemedicine, apps and wearables like smartwatches are being rapidly introduced into the mix as sponsors innovate to keep studies running.”
The GeoMap Platform is a 3-step process:
- Find the right patients online using advanced algorithms across country specific social and news media, as well as video and online search
- Screen them using the Proprietary AI Patient Screener Funnel of more than 300+ possible questions
- Connect them to sites via direct secure encrypted email to the study coordinator/s for a phone call.
The Platform is the fastest most accurate targeting tool available that doesn’t require IRB/EC approval and can start recruiting in under 24 hours.
The Platform has strict verification and email encryption so PHI is managed in accordance with state and country regulatory guidelines.
The Platform is a sophisticated location and health profile search service that sends only highly eligible people to their nearest site.